-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca's Baxfendy wins EU panel backing for hypertension treatment

PUBT·11/13/2026 11:47:21
Listen to the news
AstraZeneca's Baxfendy wins EU panel backing for hypertension treatment
  • AstraZeneca’s Baxfendy (baxdrostat) received a positive EU regulatory recommendation for adults with hypertension insufficiently controlled by at least two medications.
  • If approved, Baxfendy would become the EU’s first aldosterone synthase inhibitor.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202611130646BITN____UKPR__SV_20261112-BIT-8659-0) on November 13, 2026, and is solely responsible for the information contained therein.